Could group talk boost the benefits of psychedelic therapy for depression?

NCT ID NCT07737990

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study tests whether group therapy sessions can help people with treatment-resistant depression better integrate the insights gained from psilocybin-assisted psychotherapy. Participants who have already completed psilocybin treatment will join small groups for ten weekly sessions, each exploring a different theme. The goal is to see if this approach is acceptable and whether it improves engagement with the integration process, potentially making the therapy more resource-efficient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
psilocybin-assisted group integration psychotherapy
What this could lead to
If group therapy proves effective, it could make psilocybin-assisted psychotherapy more accessible and cost-effective for people with hard-to-treat depression.
What could go wrong
This is an early, small study without a control group, so results may not be definitive. Group dynamics could also be challenging for some participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TREATMENT RESISTANT DEPRESSION (TRD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depressive Disorder, Treatment-Resistant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Toronto Western Hospital

    Toronto, Ontario, M5T 2S8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.